Completed PHASE2 INTERVENTIONAL 4-arm NCT00488787

Safety and Efficacy of Intranasal Ketamine for the Treatment of Postoperative Dental Pain

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of 10 mg, 30 mg, and 50 mg of Transnasal Ketamine Hydrochloride (PMI-100) for the Treatment of Postoperative Dental Pain

Sponsor: Javelin Pharmaceuticals

Conditions Pain, Postoperative

Interventions intranasal ketamine placebo

Updated 6 times since 2017 Last updated: Feb 5, 2008 Started: Mar 31, 2001 Primary completion: Apr 30, 2001 Completion: Apr 30, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pain, Postoperative and is currently completed. Javelin Pharmaceuticals leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Javelin Pharmaceuticals

Data source: Javelin Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.